AIkido Pharma Inc is a biotechnology business based in the US. AIkido Pharma shares (AIKI) are listed on the NASDAQ and all prices are listed in US Dollars. AIkido Pharma employs 4 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.47 |
|---|---|
| 52-week range | $0.51 - $2.55 |
| 50-day moving average | $0.69 |
| 200-day moving average | $0.85 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.07 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.47 from 2022-01-21
| 1 week (2022-01-14) | -11.32% |
|---|---|
| 1 month (2021-12-23) | -26.56% |
| 3 months (2021-10-22) | -45.35% |
| 6 months (2021-07-23) | -46.59% |
| 1 year (2021-01-22) | -62.10% |
|---|---|
| 2 years (2020-01-23) | -59.39% |
| 3 years (2019-01-23) | 0.7546 |
| 5 years (2017-01-23) | 1.2395 |
| Revenue TTM | $9,000 |
|---|---|
| Gross profit TTM | $9,000 |
| Return on assets TTM | -7.65% |
| Return on equity TTM | -7.61% |
| Profit margin | 0% |
| Book value | $1.15 |
| Market capitalisation | $47.8 million |
TTM: trailing 12 months
We're not expecting AIkido Pharma to pay a dividend over the next 12 months.
AIkido Pharma's shares were split on a 1113:1000 basis on 27 October 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1113 shares. This wouldn't directly have changed the overall worth of your AIkido Pharma shares – just the quantity. However, indirectly, the new 10.2% lower share price could have impacted the market appetite for AIkido Pharma shares which in turn could have impacted AIkido Pharma's share price.
Over the last 12 months, AIkido Pharma's shares have ranged in value from as little as $0.51 up to $2.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AIkido Pharma's is 1.367. This would suggest that AIkido Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
AIkido Pharma Inc. , a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.